

# Treating cAD or FASS?

## Here are 3 reasons to add in ASIT...

**Allergen-specific immunotherapy (ASIT) is an important component of successful, long-term multimodal management of your canine atopic dermatitis (cAD) and feline atopic skin syndrome (FASS) patients.**

### 1 Chronic conditions deserve long-term management approaches

**Go #BeyondTheItch to help set your patients up for long-term comfort and success.**

Stopping the itch quickly is vitally important, but when it comes to providing true, lasting relief for your atopic patients, it's only part of the job. **ASIT and fast-acting antipruritic medications aren't mutually exclusive—they can work together to stop the itch now and begin to address the underlying immune system hypersensitivity driving the pathology.**<sup>1,2</sup>



### 2 Addressing the root cause could prevent progression

**Don't just treat suffering—lessen and possibly prevent it.**

Atopic dermatitis and environmental allergies are chronic, lifelong, often progressive conditions that tend to get worse in subsequent years and may involve the potential development of new allergen sensitivities over time.<sup>3</sup> **ASIT is the only treatment that has demonstrated the ability to slow, and even prevent, the progression of atopic dermatitis and environmental allergies.** ASIT also has the demonstrated potential to prevent the development of new allergen sensitivities.<sup>3-6</sup>



### 3 Quality-of-life considerations

**Bring more relief to everyone at home (and your practice).**

Let's face it, cAD and FASS are frustrating conditions for pet owners (and veterinary teams) to deal with. Studies have confirmed, and quantified, the negative impact of these conditions on pet owners.<sup>7,8</sup> The good news is that **it's been shown that multimodal management, including ASIT, can help improve the quality of life of atopic pets and their owners** to a greater degree than multimodal management that doesn't include ASIT.<sup>9</sup>



**Ready to learn more about ASIT?**

Visit [BeyondTheItch.com/pro](https://BeyondTheItch.com/pro) for additional resources.

**References:** **1.** Arcique MA, Bajwa J. Atopic dermatitis in humans and dogs. *Can Vet J.* 2020;61(1):82-84. **2.** Marsella R. Atopic dermatitis in domestic animals: what our current understanding is and how this applies to clinical practice. *Vet Sci.* 2021; 8(7):124. doi:10.3390/vetsci8070124 **3.** Marsella R, De Benedetto A. Atopic dermatitis in animals and people: an update and comparative review. *Vet Sci.* 2017;4(3):37. doi:10.3390/vetsci4030037 **4.** Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. *World Allergy Organ J.* 2015;8(1):17. doi:10.1186/s40413-015-0063-2 **5.** Ramió-Lluch L, Brazis P, Ferrer L, Puigdemont A. Allergen-specific immunotherapy in dogs with atopic dermatitis: is owner compliance the main success-limiting factor?. *Vet Rec.* 2020;187(12):493. doi:10.1136/vr.106024 **6.** Nuttall TJ, Marsella R, Rosenbaum MR, Gonzales AJ, Fadok VA. Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs. *J Am Vet Med Assoc.* 2019;254(11):1291-1300. doi:10.2460/javma.254.11.1291 **7.** Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. *Vet Dermatol.* 2010;21(5):456-462. doi:10.1111/j.1365-3164.2010.00899.x **8.** Noli C, Borio S, Varina A, Schievano C. Development and validation of a questionnaire to evaluate the quality of life of cats with skin disease and their owners, and its use in 185 cats with skin disease. *Vet Dermatol.* 2016;27(4):247-e58. doi:10.1111/vde.12341 **9.** Kotnik T. Quality of life of allergic dogs treated with allergen-specific immunotherapy—a retrospective study. *Vet Sci.* 2023; 10(2):72. doi:10.3390/vetsci10020072